Elpis BioMed

Elpis was formed in 2017 as a spin-out from the University of Cambridge. The Company provides consistent and scalable stem cell-derived cell types as an alternative to primary cells to enable scientists to carry out human cell-based research, without the need for expertise in stem cell biology.
Elpis provides differentiated human cells and tissue models for science, drug discovery, and toxicology. Elpis’ “direct cell reprogramming” technology utilises a unique optimised, inducible overexpression (OPTi-OX) approach, which reduces the manufacturing time taken to generate pure mature human cell populations from stem cells, while allowing for unprecedented levels of consistency and minimal batch-to-batch variability. The technology has already been successfully applied to the generation of several human cell types including neuronal, glial, skeletal muscle and blood precursor cells. The Company also offers sponsored development partnerships for specific human cell types that are not readily available and strategic consulting for the tailored implementation of human cell assays in target validation, drug discovery, and screening processes